Aclaris Therapeutics to present ATI-2138 atopic dermatitis trial data

March 20, 2026 11:00 AM

Aclaris Therapeutics Inc. (NASDAQ: ACRS) announced that results from its Phase 2a trial of ATI-2138 will be presented at the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found